This is not the right way to get a drug licensed
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A licensed drug tested specifically for the licensed indications is safer for patients than an unlicensed one. The efforts by Genzyme, the Sanofi subsidiary, to obtain a licence for alemtuzumab in multiple sclerosis should therefore be welcomed.
Patients would then have confidence that the drug is suitable for their condition and would not have to rely on the opinion – and necessarily limited experience – of their personal consultant.
However, Genzyme has gone about it in a way which, while potentially benefiting patients in the future, is disadvantaging them now. That is what has upset the three leading neurologists who have protested to Jeremy Hunt.
The company has not encouraged off-label use of the drug for MS, but it has tolerated it for many years. Now, abruptly, it has cut off the supply. Existing patients may find themselves unable to complete their treatment and new patients may miss it altogether.
The demands of bureaucracy have trumped the needs of patients. If, when alemtuzumab is licensed, the price rises sharply, as predicted, that will compound the pain.
Small wonder the drug industry is unloved.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments